Figure 2.

Summary of correlative studies. Effects of RAD‐001 therapy on peripheral blood‐derived parameters of immune homeostasis. Peripheral blood plasma or mononuclear cell isolates collected prior to therapy, at weeks 8 and 16 of therapy as well as at the time of tumor progression, were analyzed. For most measured parameters, RAD‐001 therapy did not appear to significantly influence the measurements; however, therapy did appear to significantly reduce the numbers of regulatory T cells (Treg) in approximately half of the treated patients. These effects were not correlated with clinical outcomes.

Abbreviation: PFS, progression‐free survival.